Target General Infomation
Target ID
T46700
Former ID
TTDR01388
Target Name
mRNA of human cot oncogene
Gene Name
MAP3K8
Synonyms
Cancer Osaka thyroid oncogene (mRNA); MAP3K8 (mRNA); Mitogenactivated protein kinase kinase kinase 8 (mRNA); Protooncogene cCot (mRNA); Serine/threonineprotein kinase cot (mRNA); TPL2 (mRNA); Tumor progression locus 2 (mRNA); MAP3K8
Target Type
Research
Function
Required for lipopolysaccharide (LPS)-induced, TLR4- mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF- alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B- cells andmacrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows sometransforming activity, although it is much weaker than that of the activated oncogenic variant.
BioChemical Class
Kinase
Target Validation
T46700
UniProt ID
EC Number
EC 2.7.11.25
Sequence
MEYMSTGSDNKEEIDLLIKHLNVSDVIDIMENLYASEEPAVYEPSLMTMCQDSNQNDERS
KSLLLSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGR
YQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVE
IQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKG
LDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVIL
CRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPG
MRELIEASLERNPNHRPRAADLLKHEALNPPREDQPRCQSLDSALLERKRLLSRKELELP
ENIADSSCTGSTEESEMLKRQRSLYIDLGALAGYFNLVRGPPTLEYG
Inhibitor 8-chloro-quinoline-3-carbonitrile Drug Info [529035]
NSC-686549 Drug Info [529213]
Tpl2 kinase inhibitor Drug Info [527741]
Pathways
KEGG Pathway MAPK signaling pathway
Toll-like receptor signaling pathway
T cell receptor signaling pathway
TNF signaling pathway
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Toll receptor signaling pathway
Pathway Interaction Database TCR signaling in na&amp
#xef
ve CD4+ T cells
TCR signaling in na&amp
ve CD8+ T cells
Role of Calcineurin-dependent NFAT signaling in lymphocytes
Ras signaling in the CD4+ TCR pathway
JNK signaling in the CD4+ TCR pathway
Reactome CD28 dependent PI3K/Akt signaling
MAP3K8 (TPL2)-dependent MAPK1/3 activation
WikiPathways Toll-like receptor signaling pathway
TCR Signaling Pathway
Insulin Signaling
MAPK Signaling Pathway
Structural Pathway of Interleukin 1 (IL-1)
TNF alpha Signaling Pathway
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in leukocytes - TarBase
miR-targeted genes in epithelium - TarBase
Interleukin-1 signaling
Costimulation by the CD28 family
Regulation of toll-like receptor signaling pathway
References
Ref 527741Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5288-92. Epub 2005 Sep 13.
Ref 529035J Biol Chem. 2007 Nov 16;282(46):33295-304. Epub 2007 Sep 11.Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.
Ref 529213Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Ref 549638US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.